$12.36
4.39%
Nasdaq, Mon, Oct 19 2026.
ISIN
US38000Q1022
Symbol
GLYC

GlycoMimetics, Inc. Stock price

$12.36
-3.89 23.94% 1M
-9.33 43.02% 6M
+0.50 4.22% YTD
-0.17 1.36% 1Y
-117.64 90.49% 3Y
-180.64 93.60% 5Y
-623.64 98.06% 10Y
-888.64 98.63% 20Y
Nasdaq, Closing price Mon, Oct 19 2026
+0.52 4.39%
ISIN
US38000Q1022
Symbol
GLYC

Is GlycoMimetics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,109 stocks worldwide.

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
-
Valuation
P/E
-
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
- | -
P/B
-
Financial Health
Equity Ratio
47.9%
Return on Equity
-712.9%
ROCE
-
ROIC
-
Debt/Equity
-
Financials
Revenue | estimate
- | $0.0
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow | ex SBC
- | -
Growth
Revenue | estimate
- | -
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
-
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
-
FCF per Share
-
Short interest
0.0%
Employees
4
Rev per Employee
$0.0

GlycoMimetics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a GlycoMimetics, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a GlycoMimetics, Inc. forecast:

Buy
86%
Hold
14%

Financial data from GlycoMimetics, Inc.

Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 18 18
5% 5%
-
- Research and Development Expense 14 14
29% 29%
-
-32 -32
17% 17%
-
- Depreciation and Amortization 0.04 0.04
73% 73%
-
EBIT (Operating Income) EBIT -33 -33
17% 17%
-
Net Profit -38 -38
3% 3%
-

In millions USD.

Don't miss a Thing! We will send you all news about GlycoMimetics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease-related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.

Head office United States
CEO Harout Semerjian
Employees 4
Founded 2003
Website glycomimetics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today